Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 06, 2026
Why Is Onterris (ONT) Stock Down -36.19% Today?

Why Is Onterris (ONT) Stock Down -36.19% Today?

Key Takeaways

  • Onterris shares plunged approximately 36.19% in Thursday's trading session, extending an after-hours rout triggered by a disappointing second-quarter earnings report and a steep cut to full-year guidance.
  • Q2 2026 results missed Wall Street estimates across the board, with revenue falling 20.4% year-over-year to $186.7 million and adjusted earnings per share of $0.04 coming in well below the $0.09 consensus.
  • Full-year revenue guidance was slashed from $840–$900 million to $740–$790 million, reflecting historically weak environmental emergency response activity, lower pass-through revenue, and temporary regulatory headwinds.
  • BofA Securities downgraded the stock from Neutral to Underperform on Thursday, cutting its price target from $31 to $18, citing accelerating deregulation risks and execution concerns.
  • The company also unveiled a poison pill and a board-led strategic review, raising questions about undisclosed share accumulation and the potential for corporate action.
  • Traders are now watching whether the stock can hold above its 52-week low of $14.13 and how the strategic review unfolds in the coming months.

Opening Summary

Shares of ONT, the environmental solutions company formerly known as Montrose Environmental Group, cratered roughly 36.19% on Thursday, sinking to approximately $14.44 after closing the prior session at $22.63. The collapse extends a punishing after-hours reaction to the company's second-quarter 2026 earnings release late Tuesday, which missed analyst expectations and included a dramatic downward revision to full-year revenue and EBITDA guidance. A subsequent analyst downgrade from BofA Securities and the surprise announcement of a stockholder rights plan compounded the selling pressure, making this one of the worst single-session performances in the company's public history.

Q2 Earnings Miss Sparks the Selloff

The rout originated after Tuesday's closing bell, when ONT reported second-quarter revenue of $186.7 million—a steep 20.4% decline from $234.5 million in the year-earlier period and well short of the $200.45 million Wall Street consensus. Adjusted earnings per share landed at just $0.04, missing the $0.09 estimate by a wide margin. The company attributed the shortfall primarily to historically low environmental emergency response and recovery service activity, which fell roughly $37.7 million year-over-year. Management stressed that the decline was driven by the timing and frequency of environmental events rather than competitive losses, but investors showed little patience for that distinction.

Although the company managed to expand its consolidated adjusted EBITDA margin by 20 basis points to 17.1%—thanks to ongoing cost-optimization efforts—the improvement was overshadowed by the sheer magnitude of the top-line miss. The Consulting & Treatment segment bore the brunt of the damage, with revenue plunging 26.8% to $125.6 million, while the Measurement & Analysis segment held relatively steady at $61.1 million, down just 2.7%.

Guidance Slashed Across the Board

Compounding the quarterly disappointment, ONT management dramatically reduced its full-year 2026 outlook. Revenue guidance was cut to a range of $740 million to $790 million, down from the previous range of $840 million to $900 million—a roughly $115 million reduction at the midpoint. Full-year EBITDA guidance was also trimmed to $117 million to $120 million from $125 million to $130 million. The guidance cut reflected three primary headwinds: approximately $45 million in lower pass-through revenue, about $40 million less emergency response revenue, and roughly $20 million in other revenue impacts tied to temporary regulatory waivers for federal and state air permitting rules.

For the third quarter, the company forecast revenue of $190 million to $210 million with EBITDA margins between 17% and 18%. While management maintained that every outcome in the updated EBITDA range would represent a company record, the market focused squarely on the downward trajectory.

BofA Downgrade Adds Fuel to the Fire

The selling intensified on Thursday after BofA Securities downgraded ONT from Neutral to Underperform and slashed its price target from $31 to $18. The firm cited accelerating federal deregulation under the current administration, arguing that a broad-based rollback of environmental regulations through the EPA and other agencies is likely to encourage private-sector companies to adopt a "wait-and-see" approach toward environmental spending. BofA also flagged execution risks, noting that recent performance and below-peer margin expansion justified a discount to target valuation multiples. The firm lowered its valuation methodology to 10 times estimated 2027 EBITDA, down from 17 times previously.

Poison Pill and Strategic Review Raise Uncertainty

In a move that added a layer of corporate intrigue, ONT announced alongside its earnings that the board had adopted a limited-duration stockholder rights plan—commonly known as a poison pill—effective immediately and expiring in August 2027. The company cited "significant and undisclosed accumulation of Onterris shares and derivative securities" as the reason. Simultaneously, the board launched a comprehensive strategic review encompassing the business portfolio, capital allocation, long-range planning, and strategic alternatives, including the possible evaluation of acquisition interest. While no decision has been made and no timeline set, the combination of a poison pill and a strategic review introduced a new layer of uncertainty that likely contributed to Thursday's selling.

Market Context and Trading Activity

Thursday's collapse was extraordinary by any measure. After falling roughly 18% in after-hours trading on Tuesday to around $18.56, the stock gapped down further at Thursday's open and continued to slide through the session, touching levels near the 52-week low of $14.13. Volume was significantly elevated, with early data suggesting trading activity well above the 10-day average of roughly 429,000 shares. The move was entirely company-specific; broader equity indices traded relatively flat on Thursday, and no sector-wide catalyst explained the magnitude of ONT's decline. The stock had been on a strong run in recent months, rallying roughly 40% over the prior three months before this week's collapse erased those gains in a single session.

What Comes Next for ONT

The immediate focus for ONT shareholders will be whether the stock can stabilize above the $14.13 52-week low, which now serves as a critical psychological and technical support level. The board's strategic review process will remain a central storyline in the months ahead, with investors watching for any indication of takeover interest, asset sales, or other value-creating transactions. Third-quarter results, expected later this fall, will provide the next major test of whether emergency response activity and regulatory-driven revenue can rebound. Key risks include the persistence of the deregulatory environment, the unpredictable nature of environmental events that drive emergency response revenue, and the execution risk inherent in the company's cost-optimization program. While management projects strong second-half cash flow generation, rebuilding investor confidence will likely require multiple quarters of improved execution.

Trending AI Robots

For traders navigating volatile situations like the one unfolding in ONT, Tickeron offers a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers. The Trending AI Robots page features only the strongest-performing bots under current market conditions, spanning a variety of strategies, timeframes, and performance metrics. Each bot is tailored to a specific trading style—whether momentum, trend-following, or mean-reversion—allowing users to find automated solutions aligned with their approach. Explore the Trending AI Robots page to discover which strategies are outperforming in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ONT

ONT in upward trend: 10-day moving average crossed above 50-day moving average on June 30, 2026

The 10-day moving average for ONT crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on ONT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ONT just turned positive on August 03, 2026. Looking at past instances where ONT's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ONT advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 199 cases where ONT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ONT moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ONT broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ONT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.858) is normal, around the industry mean (5.386). P/E Ratio (150.867) is within average values for comparable stocks, (104.706). ONT's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (2.085). ONT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.009). P/S Ratio (0.978) is also within normal values, averaging (77.083).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Enviri Corporation (NYSE:NVRI).

Industry description

Environmental Services includes companies that collect and dispose of hazardous and non-hazardous waste. Their services include removal of toxic waste from soil, removing medical waste etc. Some companies also operate incinerators, sewerage systems, waste treatment plants, and landfills. Demand for waste management is likely to rise with increasing urbanization/industrialization. Waste Management, Inc., Republic Services, Inc., Waste Connections, Inc. and Tetra Tech, Inc. are some of the major companies in this business.

Market Cap

The average market capitalization across the Environmental Services Industry is 11.75B. The market cap for tickers in the group ranges from 14.5K to 89.66B. WM holds the highest valuation in this group at 89.66B. The lowest valued company is GLYE at 14.5K.

High and low price notable news

The average weekly price growth across all stocks in the Environmental Services Industry was 7%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -10%. CDTG experienced the highest price growth at 74%, while OIO experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Environmental Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 66
Price Growth Rating: 58
SMR Rating: 87
Profit Risk Rating: 75
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
ONT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in the provision of air measurement and environmental laboratory services

Industry EnvironmentalServices

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.